Abstract
Although adjuvant therapy of melanoma with interferon alfa is widely used in different doses, schedules, and routes of administration throughout the world, the regimen remains highly controversial.1,2 The controversy centres on whether the efficacy (particularly in terms of improved survival) relative to the toxicity of therapy is sufficient to justify such routine use. Pegylated interferon, widely used for the treatment of hepatitis, seems to be at least equally efficacious as standard recombinant interferon in the treatment of metastatic melanoma, and the available evidence suggests that equi-efficacious doses have somewhat lower acute toxicity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
